New pill aims to calm deadly immune storm in rare blood disease
NCT ID NCT07339345
First seen Jan 17, 2026 · Last updated May 22, 2026 · Updated 20 times
Summary
This study tests a drug called golidocitinib for people with hemophagocytic lymphohistiocytosis (HLH), a rare condition where the immune system attacks the body. About 28 adults aged 14 to 70 with new or returning HLH will take the drug alone. The goal is to see if it can improve blood counts, reduce inflammation markers, and control the disease without needing a stem cell transplant right away.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
beijing Friendship Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100050, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.